AIN457P
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $1.5M | 90 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.5M | 90 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE III MULTICENTER STUDY OF INTRAVENOUS SECUKINUMAB TO COMPARE EFFICACY AT 16 WEEKS WITH PLACEBO AND TO ASSESS SAFETY AND TOLERABILITY UP TO 52 WEEKS IN SUBJECTS WITH ACTIVE PSORIATIC ARTH | Novartis Pharmaceuticals Corporation | $1.1M | 0 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE III MULTICENTER STUDY OF INTRAVENOUS SECUKINUMAB TO COMPARE EFFICACY AT 16 WEEKS WITH PLACEBO AND TO ASSESS SAFETY AND TOLERABILITY UP TO 52 WEEKS IN SUBJECTS WITH ACTIVE ANKYLOSING SPO | Novartis Pharmaceuticals Corporation | $380,874 | 0 |
Top Doctors Receiving Payments for AIN457P
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Ocoee, FL | $1.5M | 90 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.5M
- Total Doctors 0
- Transactions 90
About AIN457P
AIN457P is a drug associated with $1.5M in payments to 0 healthcare providers, recorded across 90 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $1.5M was paid across 90 transactions to 0 doctors.
The most common payment nature for AIN457P is "Unspecified" ($1.5M, 100.0% of total).
AIN457P is associated with 2 research studies, including "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE III MULTICENTER STUDY OF INTRAVENOUS SECUKINUMAB TO COMPARE EFFICACY AT 16 WEEKS WITH PLACEBO AND TO ASSESS SAFETY AND TOLERABILITY UP TO 52 WEEKS IN SUBJECTS WITH ACTIVE PSORIATIC ARTH" ($1.1M).